| Literature DB >> 34609299 |
Mesut Akarsu1, Soner Onem2, Ilker Turan2, Gupse Adali3, Meral Akdogan4, Murat Akyildiz5, Murat Aladag6, Yasemin Balaban7, Nilay Danis2, Murat Dayangac8, Genco Gencdal5, Hale Gokcan9, Elif Sertesen9, Merve Gurakar9, Murat Harputluoglu10, Gokhan Kabacam11, Sedat Karademir11, Murat Kiyici12, Ramazan Idilman9, Zeki Karasu2.
Abstract
The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t) ide analogs after liver transplantation.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34609299 PMCID： PMC8975456 DOI： 10.5152/tjg.2021.21608
Source DB: PubMed Journal: Turk J Gastroenterol ISSN： 1300-4948 Impact factor: 1.555